Payment overview · 2025
General Payments
$233,727.28
602 reported records · 47 companies
Healthcare provider profile · identity verified
Sangjin Oh, M.D.
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · GLEN BURNIE, MD · NPI 1316966179
Verified facts
What the public records show
CMS Open Payments records show Sangjin Oh, M.D. received $233,727.28 in general payments during 2025 across 602 reported records.
EMD Serono, Inc. accounted for 34.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 64 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Bafiertam, Briviact, Gamunex-C, Ingrezza, Nurtec Odt, Panzyga, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RYTARY as an associated drug or biological on 200 records involving 121 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rytary by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HORIZANT as an associated drug or biological on 2733 records involving 1696 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Horizant by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Privigen by this doctor in 2024.
Cycle Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Bafiertam as an associated drug or biological on 1343 records involving 850 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Bafiertam by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gamunex-C by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REYVOW as an associated drug or biological on 378 records involving 290 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Reyvow by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ingrezza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Mayzent by this doctor in 2024.
Octapharma USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 1567 records involving 974 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Panzyga by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Nuedexta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Panzyga by this doctor in 2024.
SK Life Science, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XCOPRI as an associated drug or biological on 1992 records involving 782 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Xcopri by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gammagard Liquid by this doctor in 2024.
UCB, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Briviact as an associated drug or biological on 13595 records involving 4444 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Briviact by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $81,640.31 | 34.9% | 81 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53,653.71 | 23.0% | 52 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29,361.54 | 12.6% | 62 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20,739.53 | 8.9% | 50 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13,409.37 | 5.7% | 16 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $11,972.41 | 5.1% | 17 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $8,855.25 | 3.8% | 50 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $6,969.33 | 3.0% | 19 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $1,174.57 | 0.5% | 14 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $664.44 | 0.3% | 29 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $603.69 | 0.3% | 26 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $339.78 | 0.1% | 9 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $312.37 | 0.1% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $283.79 | 0.1% | 13 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $276.77 | 0.1% | 16 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $267.38 | 0.1% | 10 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $254.61 | 0.1% | 7 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $246.97 | 0.1% | 8 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $245.43 | 0.1% | 9 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$188.09 | 0.1% | 13 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $177.52 | 0.1% | 7 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $176.37 | 0.1% | 11 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $168.42 | 0.1% | 10 | 2025 |
| Noctrix Health, Inc. | Unresolved — no canonical attribution shown | $164.48 | 0.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $158.26 | 0.1% | 7 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$154.74 | 0.1% | 6 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $152.28 | 0.1% | 5 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $119.81 | 0.1% | 5 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $118.67 | 0.1% | 4 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $116.76 | 0.1% | 6 | 2025 |
| Octapharma USA, Inc. | Unresolved — no canonical attribution shown | $113.51 | 0.1% | 5 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $94.03 | 0.0% | 4 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $81.54 | 0.0% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $68.27 | 0.0% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $56.10 | 0.0% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $53.19 | 0.0% | 2 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $46.56 | 0.0% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $46.40 | 0.0% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.98 | 0.0% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $26.49 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.61 | 0.0% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $24.89 | 0.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.33 | 0.0% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $22.73 | 0.0% | 1 | 2025 |
| Impel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $20.79 | 0.0% | 1 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $15.73 | 0.0% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $14.48 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $187,950.50 | 52 |
| Consulting Fee | $20,842.00 | 11 |
| Food and Beverage | $14,460.53 | 473 |
| Travel and Lodging | $10,379.26 | 65 |
| Education | $94.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $73,018.15 | 52 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $53,653.71 | 52 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $29,361.54 | 62 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $20,080.22 | 39 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $14,073.81 | 45 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $11,095.60 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $7,255.10 | 43 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $5,354.81 | 38 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $1,082.94 | 9 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $793.98 | 22 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $603.69 | 26 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $357.13 | 12 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $283.79 | 13 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $278.66 | 5 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $276.77 | 16 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $245.43 | 9 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $238.70 | 9 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $229.68 | 7 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $188.09 | 13 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $187.60 | 9 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | Octapharma USA, Inc., PFIZER INC. | $185.48 | 9 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $176.37 | 11 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $167.51 | 7 | 2025 |
Source payment records
|
|||||
| NIDRA Normalized: nidra |
Device | Noctrix Health, Inc. | $164.48 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $158.26 | 7 | 2025 |
Source payment records
|
|||||
| Bafiertam Normalized: bafiertam |
Drug | Cycle Pharmaceuticals Inc | $154.10 | 6 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $152.28 | 5 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $147.35 | 9 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $116.76 | 6 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $96.20 | 4 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $94.03 | 4 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $81.54 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $68.27 | 4 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $58.11 | 2 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $56.10 | 2 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $53.19 | 2 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $50.48 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.91 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $46.40 | 2 | 2025 |
Source payment records
|
|||||
| Tascenso ODT Normalized: tascenso odt |
Drug | Cycle Pharmaceuticals Inc | $42.41 | 2 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $40.85 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $28.68 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $26.98 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $26.49 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $24.89 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $23.50 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $22.73 | 1 | 2025 |
Source payment records
|
|||||
| ZONISADE Normalized: zonisade |
Drug | Azurity Pharmaceuticals, Inc. | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| TRUDHESA Normalized: trudhesa |
Drug | Impel Pharmaceuticals LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| AMYVID Normalized: amyvid |
Drug | Lilly USA, LLC | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| ONZETRA XSAIL Normalized: onzetra xsail |
Drug | Currax Pharmaceuticals LLC | $14.48 | 1 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Bafiertam bafiertam |
2025 | Bafiertam | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Briviact briviact |
2025 | Briviact | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 47 | exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 76 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
76 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | RYTARY open payments reported associated product |
CMS Open Payments — General Payments 200 supporting records · 121 recipient NPIs · example record 1220526035 |
Rytary · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | HORIZANT open payments reported associated product |
CMS Open Payments — General Payments 2733 supporting records · 1696 recipient NPIs · example record 1242666828 |
Horizant · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Cycle Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | Bafiertam open payments reported associated product |
CMS Open Payments — General Payments 1343 supporting records · 850 recipient NPIs · example record 1248898758 |
Bafiertam · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | REYVOW open payments reported associated product |
CMS Open Payments — General Payments 378 supporting records · 290 recipient NPIs · example record 1186470979 |
Reyvow · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Octapharma USA, Inc. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 1567 supporting records · 974 recipient NPIs · example record 1245074635 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
47 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SK Life Science, Inc. Exact reporting entity; no affiliate inference |
2025 | XCOPRI open payments reported associated product |
CMS Open Payments — General Payments 1992 supporting records · 782 recipient NPIs · example record 1252276115 |
Xcopri · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| UCB, Inc. Exact reporting entity; no affiliate inference |
2025 | Briviact open payments reported associated product |
CMS Open Payments — General Payments 13595 supporting records · 4444 recipient NPIs · example record 1224348489 |
Briviact · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 430 | 160 |
| Memantine Hcl | Memantine Hcl | 289 | 83 |
| Kesimpta Pen | Ofatumumab | 277 | 33 |
| Donepezil Hcl | Donepezil Hcl | 271 | 83 |
| Levetiracetam | Levetiracetam | 218 | 59 |
| Quetiapine Fumarate | Quetiapine Fumarate | 211 | 71 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 208 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 189 | 61 |
| Pregabalin | Pregabalin | 162 | 56 |
| Topiramate | Topiramate | 147 | 58 |
| Amitriptyline Hcl | Amitriptyline Hcl | 145 | 53 |
| Divalproex Sodium Er | Divalproex Sodium | 143 | 46 |
| Trazodone Hcl | Trazodone Hcl | 127 | 49 |
| Primidone | Primidone | 126 | 43 |
| Baclofen | Baclofen | 121 | 47 |
| Modafinil | Modafinil | 110 | 50 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 101 | 29 |
| Lacosamide | Lacosamide | 99 | 22 |
| Clonazepam | Clonazepam | 96 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 84 | 24 |
| Sumatriptan Succinate | Sumatriptan Succinate | 78 | 19 |
| Qulipta | Atogepant | 76 | 26 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 74 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 64 | suppressed |
| Lamotrigine | Lamotrigine | 61 | 16 |
| Diazepam | Diazepam | 60 | 17 |
| Tramadol Hcl | Tramadol Hcl | 55 | suppressed |
| Dalfampridine Er | Dalfampridine | 54 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 47 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 46 | suppressed |
| Prednisone | Prednisone | 45 | 25 |
| Oxcarbazepine | Oxcarbazepine | 42 | 12 |
| Amantadine | Amantadine Hcl | 41 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 21 |
| Xcopri | Cenobamate | 38 | suppressed |
| Armodafinil | Armodafinil | 37 | 13 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | 15 |
| Nourianz | Istradefylline | 37 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 34 | 14 |
| Carbamazepine | Carbamazepine | 34 | 15 |
| Sertraline Hcl | Sertraline Hcl | 33 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 32 | 11 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 32 | 13 |
| Emgality Pen | Galcanezumab-Gnlm | 31 | 11 |
| Horizant | Gabapentin Enacarbil | 31 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 30 | suppressed |
| Fycompa | Perampanel | 30 | suppressed |
| Olanzapine | Olanzapine | 30 | suppressed |
| Mirtazapine | Mirtazapine | 29 | 15 |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 11 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 24 | 12 |
| Memantine Hcl Er | Memantine Hcl | 24 | suppressed |
| Phenobarbital | Phenobarbital | 24 | suppressed |
| Ingrezza | Valbenazine Tosylate | 23 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Zonisamide | Zonisamide | 22 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 21 | 11 |
| Teriflunomide | Teriflunomide | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 17 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Emgality Syringe | Galcanezumab-Gnlm | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | 11 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 17 | suppressed |
| Rytary | Carbidopa/Levodopa | 17 | suppressed |
| Aubagio | Teriflunomide | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Reyvow | Lasmiditan Succinate | 16 | suppressed |
| Topiramate Er | Topiramate | 16 | suppressed |
| Bafiertam | Monomethyl Fumarate | 15 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 15 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 15 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Eszopiclone | Eszopiclone | 14 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 12 | suppressed |
| Octagam | Immun Globg(Igg)/Malt/Iga Ov50 | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 11 | suppressed |
| Mayzent | Siponimod | 11 | suppressed |
| Rufinamide | Rufinamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233,727.28 · 602 records | EMD Serono, Inc. | AMVUTTRA, AMYVID, AUSTEDO XR, AZMIRO, Albuked, BRIUMVI, Bafiertam, Briviact, CREXONT, CUTAQUIG, DAYBUE, EMGALITY, Exablate, Fintepla, GAMMAKED, Gamunex-C, HYQVIA, Hizentra, INGREZZA, INSPIRE, KEDRAB, KESIMPTA, KISUNLA, KOATE, LUMRYZ, Leqembi, Mavenclad, NEURACEQ, NIDRA, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONZETRA XSAIL, Ocrevus Zunovo, PANZYGA, PONVORY, QULIPTA, QUTENZA, REXULTI, Radicava, RhoGAM Ultra-Filtered PLUS, Rystiggo, Senza, Sunosi, Symbravo, TRUDHESA, TYSABRI, Tascenso ODT, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, ZAVZPRET, ZEPBOUND, ZEPOSIA, ZONISADE | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Bafiertam play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error